ROH-001 ophthalmic solution phase II clinical trial in patients with myopia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031250015

Enrollment

210

Registered

2025-04-18

Start date

2025-05-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Interventions

ROH-001 ophthalmic solution or placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Written informed consent from subjects guardian or legally acceptable representative have been obtained Cycloplegic objective spherical equivalent -6.00 D in both eyes Patients with progressive myopia

Exclusion criteria

Exclusion criteria: Patients who previously receive treatments for slowing myopia progression. Patients who the principal/sub investigator has determined are not suitable to participate in this study

Design outcomes

Primary

Measure	Time frame
The change in objective spherical equivalent	—

Contacts

Public ContactTomomi Mantani

ROHTO Pharmaceutical Co., Ltd.

rohtocl@rohto.co.jp+81-774-71-8802

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026